Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal ... lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. ...
2009 NOV 1 ... positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. ... lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. ...
2009 SEP 28 ... once weekly, complete the VIVITROL® pivotal study to expand the label into the opioid dependence indication and expand our pipeline of innovative medicines," said Richard Pops. "I ...
2009 SEP 14 ... dependence, who were psychiatrically stable, were randomized to receive naltrexone (opioid antagonist) and disulfiram (Antabuse) alone or in combination for 12 weeks. Results ...
Subject: US Department of Defense Congressionally Directed Medical Research Programs
2009 OCT 5 ... and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, ... reverse the effects of opioids in overdose emergencies and for the treatment of alcohol dependence. Will Rowe, CEO of the American Pain Foundation, stated, "Effective pain ...
2009 SEP 21 ... compared at equianalgesic doses with Percocet®, the second most widely prescribed opioid in the US, MoxDuo™ IR demonstrated greater overall tolerability with substantially ... stage of rnproducts under development; uncertainties relating to clinical trials; dependence on third rnparties; future capital needs; and risks relating to the ...
2009 NOV 2 ... trial with efficacy assessed during weeks 8 to 20 and follow-up to week 24. Cocaine- and opioid-dependent persons recruited from October 2003 to April 2005 from greater New Haven, ... "Cocaine dependence, which affects 2.5 million Americans annually, has no US Food and Drug ...
2009 SEP 23 ... "Physicians have embraced the concept of long-term opioid treatment for chronic noncancer pain (CNCP), as evidenced by increased prescribing," ... benefits against risks, especially in individuals at risk for opioid misuse, abuse, or dependence," wrote S. Colameco and colleagues. The researchers concluded: "This ...
2009 NOV 23 ... with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid™ formulation (MoxDuo™CR). MoxDuo™CR is designed to provide 12 hours of ... of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the ...
2009 NOV 17 ... "The mechanisms underlying opioid tolerance are not fully understood, but appear to be comprised of two types of ... Japan report. "However, the mechanisms underlying opioid tolerance and dependence are not always explained by cellular adaptation mechanisms alone. This review focuses on ...
2009 NOV 2 ... controlled trial with a 6-month follow-up period. Eligibility criteria were DSM-IV opioid (heroin) dependence; age 18 years or older; willingness to be randomized; residing in ...
2009 NOV 16 ... "Coactivation of spinal alpha(2)-adrenergic receptors (ARs) and opioid receptors produces antinociceptive synergy. Antinociceptive synergy between ... findings was confirmed in vivo, using a thermal nociceptive test, demonstrating the PKC dependence of CLON-DELT antinociceptive synergy in mice. That inhibition of CGRP release by the ...
2009 OCT 12 ... concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric ...
2009 SEP 21 ... According to a study from Ebara, Japan, "mu opioid receptor (MOR) agonists such as morphine are applied widely in clinical practice as pain ... The effects of morphine through MOR, such as analgesia and development of tolerance and dependence, are influenced by individual specificity." "Recently, we analyzed single ...
2009 SEP 14 ... ingredient in heroin, can be an effective adjunctive treatment for chronic, relapsing opioid dependence. In an open-label, phase 3, randomized, controlled trial in Canada, we compared ...
2009 OCT 5 ... (BNX) - a combination of a partial opioid agonist and an opioid antagonist for treating opioid dependence - which was specifically developed to limit injecting. Comparison was made with ...
2009 SEP 21 ... stigma. Like methadone, it prevents withdrawal symptoms when an individual stops taking opioid drugs by producing similar effects. Both methadone and buprenorphine are included in ... and Prevention, which say prisoners should be offered ORT for treatment of opiate dependence. The study's findings are published online by Drug and Alcohol Dependence. ...
2009 NOV 23 ... opiates to effectively manage pain while reducing the potential for opiate addiction. Opioid abuse is one of the many substance addiction indications covered under Catalyst's ... hospital programs for substance abuse disorders, including the development of opiate dependence used for the treatment of chronic pain. The goal of the grant is to begin to develop a ...
2009 NOV 16 ... 2005. "The drug pipeline for the addiction disorders of alcohol, cocaine, opioid, methamphetamine, phencyclidine, cannabis, and tobacco dependence is now rich with a ...
